Homology Medicines Inc

Homology Medicines Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.03
  • Today's Change-0.22 / -9.78%
  • Shares traded4.91m
  • 1 Year change-72.23%
  • Beta-0.4076
Data delayed at least 15 minutes, as of Jun 24 2022 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Homology Medicines, Inc. is a clinical-stage genetic medicines company focused on providing treatment for rare genetic diseases. The Company’s clinical programs include HMI-102, is an investigational gene therapy candidate in clinical development for the treatment of adult patients with phenylketonuria (PKU); HMI-103, which is an investigational gene editing candidate in clinical development for the treatment of patients with PKU, and HMI-203, which is an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome. Additionally, the Company is developing a gene therapy candidate, HMI-104, from its GTx-mAb platform for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), and conducting research in other diseases, including metachromatic leukodystrophy (MLD). Its platform is designed to utilize human hematopoietic stem cell derived adeno-associated virus vectors.

  • Revenue in USD (TTM)5.47m
  • Net income in USD-2.59m
  • Incorporated2015
  • Employees224.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Yoshitsu Co Ltd (ADR)221.51m5.52m45.68m54.,102,125.00--------18.04--2.49--0.83455.370.7659--58.71--12.92------
Tabula Rasa HealthCare Inc321.69m-79.96m83.49m1.60k--2.30--0.2596-3.40-3.7313.691.400.637451.667.85200,805.30-15.84-12.97-18.35-15.2227.8731.98-24.85-18.173.73-7.110.9123--11.4528.432.36--43.94--
Homology Medicines Inc5.47m-2.59m116.49m224.00--0.384925.0321.30-0.0734-0.07340.09575.270.02----24,410.71-0.7312-38.19-0.7869-41.16-----36.49-948.08----0.00--1,157.25--25.59--3.79--
Marimed Inc128.10m7.19m154.46m260.0026.953.4214.591.210.01710.01710.35080.24711.135.9023.72492,706.206.66-27.018.37-39.3954.6854.255.90-36.531.2313.900.1865--138.66102.53236.97--40.72--
Petmed Express Inc273.42m21.10m457.13m212.0021.033.2119.181.671.041.0413.436.781.505.84121.521,289,703.0011.6019.3314.7723.2828.5631.077.7210.543.57--0.0072.36-11.581.87-31.05-2.40-30.249.57
Rite Aid Corporation24.42bn-635.61m484.48m53.00k------0.0198-11.73-11.73450.77-0.15022.7310.1315.95460,789.70-7.10-3.96-10.31-5.7720.5521.12-2.60-1.580.56380.73411.00--2.181.39-438.10---5.56--
Data as of Jun 24 2022. Currency figures normalised to Homology Medicines Inc's reporting currency: US Dollar USD

Institutional shareholders

28.83%Per cent of shares held by top holders
HolderShares% Held
Temasek Holdings Pte Ltd. (Investment Management)as of 31 Mar 20225.65m9.85%
BlackRock Fund Advisorsas of 31 Mar 20223.26m5.68%
The Vanguard Group, Inc.as of 31 Mar 20221.73m3.01%
Bellevue Asset Management AGas of 31 Mar 20221.65m2.87%
SSgA Funds Management, Inc.as of 31 Mar 2022990.91k1.73%
Fidelity Management & Research Co. LLCas of 31 Mar 2022856.44k1.49%
Geode Capital Management LLCas of 31 Mar 2022816.59k1.42%
JPMorgan Asset Management (UK) Ltd.as of 31 Mar 2022682.23k1.19%
Jacobs Levy Equity Management, Inc.as of 31 Mar 2022477.64k0.83%
Citadel Advisors LLCas of 31 Mar 2022435.77k0.76%
More ▼
Data from 31 Mar 2022 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.